RGEN Repligen Corporation

206.1
+1.94  (+1%)
Previous Close 204.16
Open 202.01
52 Week Low 95.505
52 Week High 228.835
Market Cap $11,288,373,792
Shares 54,771,343
Float 48,727,137
Enterprise Value $10,740,241,386
Volume 229,942
Av. Daily Volume 409,156
Stock charts supplied by TradingView

Drug Pipeline

Drug Stage Notes
RG1068
Detection of pancreatic duct abnormalities
CRL
CRL
CRL received June 22, 2012.

Latest News

  1. WALTHAM, Mass., March 17, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virtually at the KeyBanc Life Science and MedTech Investor Forum being held March 23-24.  Tony Hunt, President & Chief Executive Officer, will participate in a fireside chat on Wednesday, March 24, at 9:15 a.m. EDT.

    A live webcast of the discussion will be accessible through the Investor Relations section of the Company's website, and will be available for replay for a limited period of time following the conference event.

    About Repligen Corporation

    Repligen Corporation is a global life sciences company that develops and commercializes highly innovative…

    WALTHAM, Mass., March 17, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virtually at the KeyBanc Life Science and MedTech Investor Forum being held March 23-24.  Tony Hunt, President & Chief Executive Officer, will participate in a fireside chat on Wednesday, March 24, at 9:15 a.m. EDT.

    A live webcast of the discussion will be accessible through the Investor Relations section of the Company's website, and will be available for replay for a limited period of time following the conference event.

    About Repligen Corporation

    Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that increase efficiencies in the process of manufacturing biological drugs. Our primary customers are biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our corporate headquarters are located in Waltham, Massachusetts, with additional administrative and manufacturing operations worldwide. The majority of our manufacturing sites are located within the U.S. (California, Massachusetts, New Jersey and New York), and outside of the U.S. we have sites in Estonia, Germany, Ireland, the Netherlands and Sweden.

    Repligen Contact:

    Sondra S. Newman

    Global Head of Investor Relations

    (781) 419-1881



    Primary Logo

    View Full Article Hide Full Article
  2. WALTHAM, Mass., March 03, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virtually at the Barclays Global Healthcare Conference being held March 9-11. Jon Snodgres, Chief Financial Officer, will participate in a fireside chat on Wednesday, March 10, at 1:50 p.m. EST.

    A live webcast of the discussion will be accessible through the Investor Relations section of the Company's website, and will be available for replay for a limited period of time following the conference event.

    About Repligen Corporation

    Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing…

    WALTHAM, Mass., March 03, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virtually at the Barclays Global Healthcare Conference being held March 9-11. Jon Snodgres, Chief Financial Officer, will participate in a fireside chat on Wednesday, March 10, at 1:50 p.m. EST.

    A live webcast of the discussion will be accessible through the Investor Relations section of the Company's website, and will be available for replay for a limited period of time following the conference event.

    About Repligen Corporation

    Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that increase efficiencies in the process of manufacturing biological drugs. Our primary customers are biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our corporate headquarters are located in Waltham, Massachusetts, with additional administrative and manufacturing operations worldwide. The majority of our manufacturing sites are located within the U.S. (California, Massachusetts, New Jersey and New York), and outside of the U.S. we have sites in Estonia, Germany, Ireland, the Netherlands and Sweden.

    Repligen Contact:

    Sondra S. Newman

    Global Head of Investor Relations

    (781) 419-1881



    Primary Logo

    View Full Article Hide Full Article
    • Reports quarterly revenue of $108.6 million, representing 56% year-over-year growth, and annual revenue of $366.3 million represents 36% year-over-year growth
    • Organic revenue growth was 47% for the fourth quarter and 29% for the year 2020

    WALTHAM, Mass., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its fourth quarter and full year 2020. Provided in this press release are financial highlights for the three - and twelve-month periods ended December 31, 2020, followed by our current financial guidance for the year 2021, and access information for today's webcast and conference call.

    Tony J. Hunt, President and Chief…

    • Reports quarterly revenue of $108.6 million, representing 56% year-over-year growth, and annual revenue of $366.3 million represents 36% year-over-year growth

    • Organic revenue growth was 47% for the fourth quarter and 29% for the year 2020

    WALTHAM, Mass., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its fourth quarter and full year 2020. Provided in this press release are financial highlights for the three - and twelve-month periods ended December 31, 2020, followed by our current financial guidance for the year 2021, and access information for today's webcast and conference call.

    Tony J. Hunt, President and Chief Executive Officer said, "We are delighted with the way we finished off 2020 with 47% organic growth in the fourth quarter and 29% for the full year. Sales into COVID vaccine and therapeutic accounts were a major contributor to overall growth especially in the second half of 2020. Our non-COVID markets also performed well, up over 18% in 2020. All our franchises delivered robust growth during the year, and we continued to see traction at gene therapy accounts. Strategically, our three acquisitions position us well to accelerate growth in our systems and fluid management businesses in 2021. With a very strong order load and COVID tailwinds, we anticipate that 2021 will be another excellent year for the company as we build additional manufacturing capacity, support the manufacturing of COVID vaccines and therapeutics and launch exciting new products."

    Fourth Quarter 2020 Highlights 

    • Revenue increased by 56% year-over-year as reported and 47% organically, to $108.6 million
    • GAAP operating margin was 16.0%, an increase of 750 bps
    • Adjusted (non-GAAP) operating margin was 25.1%, an increase of 680 bps
    • GAAP fully diluted EPS was $0.36 compared to $0.07 for the fourth quarter of 2019
    • Adjusted (non-GAAP) fully diluted EPS increased to $0.52 compared to $0.20 for the fourth quarter of 2019

    Financial Details for the Fourth Quarter and Full Year 2020

                 

    REVENUE     

    • Total revenue for the fourth quarter of 2020 increased to $108.6 million compared to $69.5 million for the fourth quarter of 2019, a year-over-year gain of 56% as reported and 53% at constant currency, with organic growth of 47%.
    • Total revenue for the full year 2020 increased to $366.3 million compared to $270.2 million for the full year 2019, a year-over-year gain of 36% as reported and 35% at constant currency, with organic growth of 29%.

    GROSS PROFIT and GROSS MARGIN 

    • Gross profit (GAAP) for the fourth quarter of 2020 was $60.5 million, a year-over-year increase of $21.1 million. Adjusted gross profit (non-GAAP) for the fourth quarter of 2020 was $61.1 million, a year-over-year increase of $21.4 million, or 53.7%.
    • Gross margin (GAAP) for the fourth quarter of 2020 was 55.7%, compared to 56.6% for the fourth quarter of 2019. Adjusted gross margin (non-GAAP) for the fourth quarter was 56.3%, compared to 57.2% to the 2019 period.
    • Gross profit (GAAP) for the full year 2020 was $209.6 million, a year-over-year increase of $58.5 million. Adjusted gross profit (non-GAAP) for the full year 2020 was $211.1 million, a year-over-year increase of $57.0 million, or 37%.
    • Gross margin (GAAP) was 57.2% for the full year 2020, a 130 bps improvement from the full year 2019. Adjusted gross margin (non-GAAP) for the full year 2020 was 57.6%, a 60 bps improvement from the full year 2019.

    OPERATING INCOME

    • Operating income (GAAP) for the fourth quarter of 2020 was $17.4 million compared to $5.9 million for the fourth quarter of 2019. Adjusted operating income (non-GAAP) for the fourth quarter of 2020 was $27.3 million, an increase of 115% compared to $12.7 million for the fourth quarter of 2019.
    • Operating income (GAAP) for the full year 2020 was $69.8 million, an increase of 94% compared to $36.1 million for the full year 2019. Adjusted operating income (non-GAAP) for the full year 2020 was $98.1 million, an increase of 54% compared to $63.5 million for the full year 2019.  
    • Operating margin (GAAP) was 16% for the fourth quarter of 2020, an increase of 750 bps year-over year. Adjusted operating margin (non-GAAP) was 25.1% for the fourth quarter of 2020, an increase of 680 bps year-over year.
    • Operating margin (GAAP) was 19.1% for the full year 2020, an increase of 570 bps year-over-year. Adjusted operating margin (non-GAAP) was 26.8% for the full year 2020, an increase of 330 bps year-over-year.

    NET INCOME

    • Net income (GAAP) for the fourth quarter of 2020 was $19.7 million compared to $3.6 million for the fourth quarter of 2019. Adjusted net income (non-GAAP) for the fourth quarter of 2020 was to $28.7 million, an increase of 165% compared to $10.8 million for the fourth quarter of 2019.  
    • Net income (GAAP) for the full year 2020 was $59.9 million, an increase of 180% compared to $21.4 million for the full year 2019. Adjusted net income (non-GAAP) for the full year 2020 was $89.1 million, an increase of 70% compared to $52.5 million for the full year 2019. 

    EARNINGS PER SHARE

    • Earnings per share (GAAP) for the fourth quarter of 2020 were $0.36 on a fully diluted basis, compared to $0.07 for the fourth quarter of 2019. Adjusted EPS (non-GAAP) for the fourth quarter of 2020 increased to $0.52 on a fully diluted basis, compared to $0.20 for the 2019 period.
    • Earnings per share (GAAP) for the full year 2020 increased to $1.11 on a fully diluted basis, compared to $0.44 for the full year 2019. Adjusted EPS (non-GAAP) for the full year 2020 increased to $1.65 on a fully diluted basis, compared to $1.07 for the full year 2019.

    EBITDA

    • EBITDA, a non-GAAP financial measure, for the fourth quarter of 2020 was $25.3 million compared to $11.7 million for the fourth quarter of 2019. Adjusted EBITDA for the fourth quarter of 2020 was $29.8 million, an increase of 104% compared to $14.6 million for the fourth quarter of 2019.
    • EBITDA for the full year 2020 was $96.6 million, an increase of 90% compared to $51.0 million for the full year 2019. Adjusted EBITDA for the full year 2020 was $107.9 million, an increase of 52% compared to $71.1 million for the full year 2019.

    CASH

    • Our cash and cash equivalents at December 31, 2020 were $717.3 million, an increase of $188.9 million from $528.4 million at December 31, 2019.   

    All reconciliations of GAAP to adjusted (non-GAAP) figures above, as well as EBITDA to adjusted EBITDA, are detailed in the reconciliation tables included later in this press release.  

    Financial Guidance for 2021

    Our financial guidance for the fiscal year 2021 is based on expectations for our existing business and includes the financial impact of our 2020 acquisitions of ARTeSYN Biosolutions (which closed on December 3, 2020), Non-Metallic Solutions (which closed on October 20, 2020 ) and Engineered Molding Technologies (which closed on July 13, 2020). The guidance below excludes the impact of potential additional acquisitions and future fluctuations in foreign currency exchange rates. 

    FISCAL YEAR 2021 GUIDANCE:  

    • Total revenue is expected to be in the range of $500-$525 million, reflecting overall revenue growth of 37%-43% as reported and at constant currency and organic growth of 26%-33%. 
    • Revenue contribution from COVID-related programs are expected to be in the range of $90-$100 million, representing incremental COVID related revenue of $44-$54 million and 12%-15% points of overall revenue growth. Incremental acquisition-related revenue is expected to be in the range of $37-$40 million, representing 10%-11% points of overall revenue growth.
    • Gross margin is expected to be 57%-58% on both a GAAP and non-GAAP basis.
    • Income from operations is expected to be in the range of $103-$109 million on a GAAP basis. Adjusted (non-GAAP) income from operations is expected to be in the range of $134-$140 million.
    • Net income is expected to be in the range of $74-$79 million on a GAAP basis. Adjusted (non-GAAP) net income is expected to be in the range of $106-$111 million. Our current guidance reflects a tax rate of 20% on adjusted pre-tax income.
    • Fully diluted GAAP EPS is expected to be in the range of $1.30-$1.38. Adjusted (non-GAAP) fully diluted EPS is expected to be in the range of $1.86-$1.94.

    Our non-GAAP guidance for the fiscal year 2021 excludes the following items: 

    • $5.8 million estimated acquisition and integration expenses; $0.1 million in cost of product revenue, $1.0 million in R&D and $4.7 million in SG&A.
    • $23.9 million estimated intangible amortization expense in SG&A.
    • Expected inventory step-up charges of $1.4 million related to 2020 acquisitions.
    • $11.0 million of non-cash interest expense (Other income (expense)) related to our convertible debt notes.

    Our non-GAAP guidance for the fiscal year 2021 includes:

    • An income tax increase of $9.8 million, representing the tax impact of acquisition and integration costs, inventory step-up changes, intangible amortization and non-cash interest.

    All reconciliations of GAAP to adjusted (non-GAAP) guidance are detailed in the tables included later in this press release.  

    Conference Call

    Repligen will host a conference call and webcast today, February 24, 2021, at 8:30 a.m. EST, to discuss fourth quarter and full year 2020 financial results and corporate developments. The conference call will be accessible by dialing toll-free (844) 274-3999 for domestic callers or (412) 317-5607 for international callers. No passcode is required for the live call. In addition, a webcast will be accessible via the Investor Relations section of the Company's website. Both the conference call and webcast will be archived for a period of time following the live event. The replay dial-in numbers are (877) 344-7529 from the U.S., (855) 669-9658 from Canada and (412) 317-0088 for international callers. Replay listeners must provide the passcode 10151931. 

    Non-GAAP Measures of Financial Performance

    To supplement our financial statements, which are presented on the basis of U.S. generally accepted accounting principles (GAAP), the following non-GAAP measures of financial performance are included in this release: revenue growth rate at constant currency, adjusted gross profit and adjusted gross margin, adjusted income from operations and adjusted operating margin, earnings before interest, taxes, depreciation and amortization (EBITDA), adjusted EBITDA, adjusted net income, adjusted net income per share, adjusted earnings per diluted share (EPS), adjusted cost of sales, adjusted research & development expense, adjusted SG&A, adjusted income tax expense and adjusted income tax rate. The Company provides organic revenue growth rates in constant currency to exclude the impact of both foreign currency translation, and the impact of acquisition revenue for current year periods that have no prior year comparable, in order to facilitate a comparison of its current revenue performance to its past revenue performance. The Company provides revenue growth rates in constant currency in order to facilitate a comparison of its current revenue performance to its past revenue performance. To calculate revenue growth rates in constant currency, the Company converts actual net sales from local currency to U.S. dollars using constant foreign currency exchange rates in the current and prior period.

    The Company's non-GAAP financial results and/or non-GAAP guidance exclude the impact of: acquisition and integration costs, inventory step-up charges and intangible amortization costs related to the Company's acquisitions, as well as non-cash interest expenses related to the Company's convertible debt, and the related impact on tax of non-GAAP charges. These costs are excluded because management believes that such expenses do not have a direct correlation to future business operations, nor do the resulting charges recorded accurately reflect the performance of our ongoing operations for the period in which such charges are recorded.

    A reconciliation of GAAP to adjusted non-GAAP financial measures is included as an attachment to this press release. When analyzing the Company's operating performance and guidance investors should not consider non-GAAP measures as substitutable for the comparable financial measures prepared in accordance with GAAP.

    About Repligen Corporation

    Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that increase efficiencies in the process of manufacturing biological drugs. Our primary customers are biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our corporate headquarters are located in Waltham, Massachusetts, with additional administrative and manufacturing operations worldwide. The majority of our manufacturing sites are located within the U.S. (California, Massachusetts, New Jersey and New York), and outside of the U.S. we have sites in Estonia, Germany, Ireland, the Netherlands and Sweden.

    The following constitutes a "Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements, which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Investors are cautioned that statements in this press release which are not strictly historical statements, including, without limitation, express or implied statements or guidance regarding current or future financial performance and position, including cash and investment position, demand in the markets in which we operate, the expected performance of our business, the expected performance of the Engineered Molding Technology, Non-Metallic Solutions and ARTeSYN Biosolutions businesses, the expected performance and success of our strategic partnerships, management's strategy, plans and objectives for future operations or acquisitions, product development and sales, selling, general and administrative expenditures, intellectual property, development and manufacturing plans, availability of materials and product and adequacy of capital resources, our financing plans, and the projected impact of, and response to, the COVID-19 coronavirus pandemic on our business and on the U.S. and global economies constitute forward-looking statements identified by words like "believe," "expect," "may," "will," "should," "seek," "anticipate," "projected," "estimated" or "could" and similar expressions. Forward-looking statements are neither historical facts nor assurances of future performance. Because forward-looking statements relate to the future, they are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including, without limitation, risks associated with the following: the effect of the COVID-19 coronavirus pandemic, including mitigation efforts and economic effects, on our business operations and the operations of our customers and suppliers; the ultimate impact of the COVID-19 coronavirus pandemic on our business or financial results; our ability to successfully grow our bioprocessing business, including as a result of acquisition, commercialization or partnership opportunities; our ability to successfully integrate any acquisitions, our ability to develop and commercialize products and the market acceptance of our products; our ability to integrate the Engineered Molding Technology, Non-Metallic Solutions and ARTeSYN Biosolutions businesses successfully into our business and achieve the expected benefits of the acquisitions; reduced demand for our products that adversely impacts our future revenues, cash flows, results of operations and financial condition; our ability to compete with larger, better financed bioprocessing, pharmaceutical and biotechnology companies; our compliance with all U.S. Food and Drug Administration and EMEA regulations; our volatile stock price; and other risks detailed in Repligen's Annual Report on Form 10-K for the year ended December 31, 2020 on file with the Securities and Exchange Commission and the other reports that Repligen periodically files with the Securities and Exchange Commission. Actual results may differ materially from those Repligen contemplated by these forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. These forward-looking statements reflect management's current views, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions, and is based on only on information currently available to us. Repligen does not undertake to update, whether written or oral, any of these forward-looking statements to reflect a change in its views or events or circumstances, whether as a result of new information, future development or otherwise, that occur after the date hereof except as required by law. 

    Repligen Contact: 

    Sondra S. Newman

    Global Head of Investor Relations

    (781) 419-1881

     





    REPLIGEN CORPORATION 
    CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS 
    (Unaudited, amounts in thousands, except share and per share data) 
           
     Three Months Ended

    December 31,
     Twelve Months Ended

    December 31,
     
      2020   2019   2020   2019  
             
    Revenue:        
    Product revenue$108,615  $69,396  $366,136  $270,097  
    Royalty and other revenue 33   78   124   148  
    Total revenue 108,648   69,474   366,260   270,245  
    Costs and expenses:        
    Cost of product revenue 48,163   30,121   156,634   119,099  
    Research and development 6,722   5,172   20,182   19,450  
    Selling, general and administrative 36,344   28,287   119,621   95,613  
      91,229   63,580   296,437   234,162  
    Income from operations 17,419   5,894   69,823   36,083  
    Investment income 42   1,708   1,741   5,324  
    Loss on extinguishment of debt -   -   -   (5,650) 
    Interest expense (3,101)  (2,966)  (12,133)  (9,292) 
    Other income (expense), net 418   (291)  (214)  (314) 
    Income before income taxes 14,778   4,345   59,217   26,151  
    Income tax (benefit) provision (4,920)  741   (709)  4,740  
    Net income$19,698  $3,604  $59,926  $21,411  
    Earnings per share:        
    Basic$0.37  $0.07  $1.14  $0.44  
    Diluted$0.36  $0.07  $1.11  $0.44  
    Weighted average shares outstanding:        
    Basic 53,143,302   52,063,528   52,553,799   48,342,584  
    Diluted 55,022,355   52,976,271   53,892,261   49,206,242  
             
             
    Balance Sheet Data:December 31, 2020 December 31, 2019     
    Cash, cash equivalents and marketable securities$717,292  $528,392      
    Working capital 583,426   593,515      
    Total assets 1,902,887   1,400,113      
    Long-term obligations 54,781   292,032      
    Accumulated earnings 65,769   5,843      
    Stockholders' equity 1,529,150   1,059,768      



    REPLIGEN CORPORATION 
    RECONCILIATION OF GAAP INCOME FROM OPERATIONS TO NON-GAAP (ADJUSTED) INCOME FROM OPERATIONS 
    (Unaudited, amounts in thousands) 
              
      Three Months Ended

    December 31,
     Twelve Months Ended

    December 31,
     
       2020   2019   2020   2019  
              
    GAAP INCOME FROM OPERATIONS$17,419  $5,894  $69,823  $36,083  
              
    ADJUSTMENTS TO INCOME (LOSS) FROM OPERATIONS:        
     Acquisition and integration costs 4,929   2,934   11,465   12,508  
     Intangible amortization 4,355   3,879   16,032   13,441  
     Inventory step-up charges 590   -   734   1,483  
              
    ADJUSTED INCOME FROM OPERATIONS$27,293  $12,707  $98,054  $63,515  
              
              
    REPLIGEN CORPORATION 
    RECONCILIATION OF GAAP NET INCOME TO NON-GAAP (ADJUSTED) NET INCOME 
    (Unaudited, amounts in thousands) 
              
      Three Months Ended December 31, Twelve Months Ended December 31, 
       2020   2019   2020   2019  
              
    GAAP NET INCOME$19,698  $3,604  $59,926  $21,411  
              
    ADJUSTMENTS TO NET INCOME:        
     Acquisition and integration costs 3,943   2,934   10,479   13,008  
     Inventory step-up charges 590   -   734   1,483  
     Intangible amortization 4,355   3,879   16,032   13,441  
     Loss on extinguishment of debt -   -   -   5,650  
     Non-cash interest expense 2,796   2,674   10,970   7,536  
     Tax effect of non-GAAP charges (2,716)  (2,261)  (9,050)  (10,003) 
              
    ADJUSTED NET INCOME$28,666  $10,830  $89,091  $52,526  
              
              
    REPLIGEN CORPORATION 
    RECONCILIATION OF GAAP NET INCOME PER SHARE TO NON-GAAP (ADJUSTED) NET INCOME PER SHARE 
    (Unaudited) 
              
      Three Months Ended December 31, Twelve Months Ended December 31, 
       2020   2019   2020   2019  
              
    GAAP NET INCOME PER SHARE - DILUTED$0.36  $0.07  $1.11  $0.44  
              
    ADJUSTMENTS TO NET INCOME PER SHARE - DILUTED:        
     Acquisition and integration costs 0.07   0.06   0.19   0.26  
     Inventory step-up charges 0.01   -   0.01   0.03  
     Intangible amortization 0.08   0.07   0.30   0.27  
     Loss on extinguishment of debt -   -   -   0.11  
     Non-cash interest expense 0.05   0.05   0.20   0.15  
     Tax effect of non-GAAP charges (0.05)  (0.04)  (0.17)  (0.20) 
              
    ADJUSTED NET INCOME PER SHARE - DILUTED 0.52  $0.20  $1.65  $1.07  
              
    Totals may not add due to rounding.        
              
              
    REPLIGEN CORPORATION 
    RECONCILIATION OF GAAP NET INCOME TO ADJUSTED EBITDA 
    (Unaudited, amounts in thousands) 
              
      Three Months Ended December 31, Twelve Months Ended December 31, 
       2020   2019   2020   2019  
              
    GAAP NET INCOME$19,698  $3,604  $59,926  $21,411  
              
    ADJUSTMENTS:        
     Investment Income (42)  (1,708)  (1,741)  (5,324) 
     Interest Expense 3,101   2,966   12,133   9,292  
     Tax Provision (4,920)  741   (709)  4,740  
     Depreciation 3,068   2,170   10,888   7,317  
     Amortization(1) 4,383   3,907   16,143   13,551  
              
    EBITDA 25,287   11,680   96,640   50,987  
              
    OTHER ADJUSTMENTS:        
     Acquisition and integration costs 3,943   2,934   10,479   13,008  
     Loss on extinguishment of debt -   -   -   5,650  
     Inventory step-up charges 590   -   734   1,483  
              
              
    ADJUSTED EBITDA$29,821  $14,614  $107,853  $71,128  
              
    (1)Includes amortization of milestone payments in accordance with GAAP of $28 and $111 for the three- and twelve-month periods,.
     respectively.        
              
    REPLIGEN CORPORATION 
    RECONCILIATION OF GAAP COST OF SALES TO NON-GAAP (ADJUSTED) COST OF SALES 
    (Unaudited, amounts in thousands) 
              
      Three Months Ended December 31, Twelve Months Ended December 31, 
       2020   2019   2020   2019  
              
    GAAP COST OF SALES$48,163  $30,121  $156,634  $119,099  
              
    ADJUSTMENT TO COST OF SALES:        
     Acquisition and integration costs (40)  (281)  (508)  (951) 
     Inventory step-up charges (590)  -   (734)  (1,483) 
     Intangible amortization -   (128)  (254)  (520) 
              
    ADJUSTED COST OF SALES$47,533  $29,712  $155,138  $116,145  
              
              
    REPLIGEN CORPORATION 
    RECONCILIATION OF GAAP R&D EXPENSE TO NON-GAAP (ADJUSTED) R&D EXPENSE 
    (Unaudited, amounts in thousands) 
              
      Three Months Ended December 31, Twelve Months Ended December 31, 
       2020   2019   2020   2019  
              
    GAAP R&D$6,722  $5,172  $20,182  $19,450  
              
    ADJUSTMENT TO R&D:        
     Acquisition and integration costs (53)  (282)  (525)  (687) 
              
    ADJUSTED R&D$6,669  $4,890  $19,657  $18,763  
              
              
    REPLIGEN CORPORATION 
    RECONCILIATION OF GAAP SG&A EXPENSE TO NON-GAAP (ADJUSTED) SG&A EXPENSE 
    (Unaudited, amounts in thousands) 
              
      Three Months Ended December 31, Twelve Months Ended December 31, 
       2020   2019   2020   2019  
              
    GAAP SG&A EXPENSE$36,344  $28,287  $119,621  $95,613  
              
    ADJUSTMENTS TO SG&A EXPENSE:        
     Acquisition and integration costs (4,836)  (2,371)  (10,432)  (10,870) 
     Intangible amortization (4,354)  (3,751)  (15,779)  (12,921) 
              
    ADJUSTED SG&A EXPENSE$27,154  $22,165  $93,411  $71,822  
              



           
     REPLIGEN CORPORATION 
     RECONCILIATION OF GAAP NET INCOME GUIDANCE TO ADJUSTED (NON-GAAP NET INCOME GUIDANCE) 
           
     (in thousands)Twelve months ending December 31, 2021 
       Low End High End 
     GUIDANCE ON NET INCOME$74,000  $79,000  
     ADJUSTMENTS TO GUIDANCE ON NET INCOME:    
      Acquisition and integration costs 5,754   5,754  
      Anticipated pre-tax amortization of acquisition-related intangible assets 23,896   23,896  
      Inventory step-up costs 1,430   1,430  
      Non-cash interest expense 10,957   10,957  
      Tax effect of non-GAAP charges (9,774)  (9,774) 
      Guidance rounding adjustment (263)  (263) 
     GUIDANCE ON ADJUSTED NET INCOME$106,000  $111,000  
           
           
     REPLIGEN CORPORATION 
     RECONCILIATION OF GAAP NET INCOME PER SHARE GUIDANCE TO  
     ADJUSTED (NON-GAAP) NET INCOME PER SHARE GUIDANCE 
           
       Twelve months ending December 31, 2021 
       Low End High End 
     GUIDANCE ON NET INCOME PER SHARE - DILUTED$1.30  $1.38  
     ADJUSTMENTS TO GUIDANCE ON NET INCOME PER SHARE - DILUTED:   
      Acquisition and integration costs$0.10  $0.10  
      Anticipated pre-tax amortization of acquisition-related intangible assets$0.42  $0.42  
      Inventory step-up costs$0.03  $0.03  
      Non-cash interest expense$0.19  $0.19  
      Tax effect of non-GAAP charges($0.17) ($0.17) 
      Guidance rounding adjustment($0.00) ($0.00) 
     GUIDANCE ON ADJUSTED NET INCOME PER SHARE - DILUTED$1.86  $1.94  
           
     Totals may not add due to rounding.    
           


    Primary Logo

    View Full Article Hide Full Article
  3. WALTHAM, Mass., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virtually at the 10th Annual SVB Leerink Healthcare conference being held February 22-26.  Tony J. Hunt, President and Chief Executive Officer, will participate in a fireside chat on Friday, February 26, at 12:00 p.m. EST.

    A live webcast of the discussion will be accessible through the Investor Relations section of the Company's website, and will be available for replay for a limited period of time following the conference event.

    About Repligen Corporation

    Repligen Corporation is a global life sciences company that develops and commercializes highly…

    WALTHAM, Mass., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virtually at the 10th Annual SVB Leerink Healthcare conference being held February 22-26.  Tony J. Hunt, President and Chief Executive Officer, will participate in a fireside chat on Friday, February 26, at 12:00 p.m. EST.

    A live webcast of the discussion will be accessible through the Investor Relations section of the Company's website, and will be available for replay for a limited period of time following the conference event.

    About Repligen Corporation

    Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that increase efficiencies in the process of manufacturing biological drugs. Our primary customers are biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our corporate headquarters are located in Waltham, Massachusetts, with additional administrative and manufacturing operations worldwide. The majority of our manufacturing sites are located within the U.S. (California, Massachusetts, New Jersey and New York), and outside of the U.S. we have sites in Estonia, Germany, Ireland, the Netherlands and Sweden.

    Repligen Contact:

    Sondra S. Newman

    Global Head of Investor Relations

    (781) 419-1881



    Primary Logo

    View Full Article Hide Full Article
  4. Webcast and Conference Call to Be Held Wednesday, February 24, 2021 at 8:30 a.m. EST

    WALTHAM, Mass., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its fourth quarter and full year 2020 financial results on Wednesday, February 24, 2021. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. EST to discuss business updates and financial results for the three- and twelve- month reporting periods ended December 31, 2020.

    The conference call will be accessible by dialing toll-free (844) 274-3999 for domestic callers and (412) 317-5607 for international callers. No passcode is required for the live call. In addition, a webcast will…

    Webcast and Conference Call to Be Held Wednesday, February 24, 2021 at 8:30 a.m. EST



    WALTHAM, Mass., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its fourth quarter and full year 2020 financial results on Wednesday, February 24, 2021. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. EST to discuss business updates and financial results for the three- and twelve- month reporting periods ended December 31, 2020.



    The conference call will be accessible by dialing toll-free (844) 274-3999 for domestic callers and (412) 317-5607 for international callers. No passcode is required for the live call. In addition, a webcast will be accessible via the Investor Relations section of the Company's website. Both the conference call and webcast will be archived for a period of time following the live event. The replay dial-in numbers are (877) 344-7529 for callers in the U.S., (855) 669-9658 for callers in Canada and (412) 317-0088 for international callers. Replay listeners must provide the passcode 10151931.



    About Repligen Corporation



    Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that increase efficiencies in the process of manufacturing biological drugs. Our primary customers are biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our corporate headquarters are located in Waltham, Massachusetts, with additional administrative and manufacturing operations worldwide. The majority of our manufacturing sites are located in the U.S. (California, Massachusetts, New Jersey and New York), and outside of the U.S. we have sites in Estonia, Germany, Ireland, the Netherlands and Sweden.



    This press release may contain forward-looking statements within the meaning of the federal securities laws. Investors are cautioned that statements in this press release which are not strictly historical statements including, without limitation, statements identified by words like "believe," "expect," "may," "will," "should," "seek," or "could" and similar expressions, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including risks discussed from time to time in our filings with the Securities and Exchange Commission. We expressly disclaim any responsibility to update any forward-looking statements, except as required by law.



    Repligen Contact:

    Sondra S. Newman

    Global Head of Investor Relations

    (781) 419-1881



    Primary Logo

    View Full Article Hide Full Article
View All Repligen Corporation News